NCODA News - Oral Oncolytics & Medically-Integrated Oncology

NEWS

Advancements in Patient-Centered Care

Stay up to date with the latest advancements in oral oncolytics, medically-integrated oncology, and cancer care best practices.

FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis

May 25, 2023 | Katie Edmiston

May 22, 2023 at 4:04 PM EDT — For the first time, patients with indolent SM have a medicine that treats the primary disease driver and is proven to provide broad and durable symptom relief — — Approval based on the positive PIONEER trial, in which once-daily AYVAKIT achieved significant improvements in disease symptoms and […]

CMS Guidance on Practices Delivering Medications Violating the Stark Law

April 27, 2023 | Katie Edmiston

[CAZENOVIA, NY – April 27, 2023] – NCODA urges the Centers for Medicare & Medicaid Services (CMS) to immediately retract a portion of a Frequently Asked Questions (FAQ) that suggests that physician practices mailing medications would violate the federal prohibition on self-referral for ancillary services (Stark law). At present, the Public Health Emergency (PHE) that […]

New Oncology Pharmacy Course to Fulfill Vital Training Need for Future Professionals

March 30, 2023 | Katie Edmiston

[CAZENOVIA, NY – March 30, 2023] – NCODA University, a division of NCODA that provides top-tier education for future and present oncology pharmacists, has launched a new 15-hour Oncology Basics Course. This first-of-its-kind course will reinforce knowledge of the etiology and pathophysiology of cancer, provide a deeper understanding of commonly used anti-cancer drug classes, and […]

Three Leading Cancer Centers Awarded Medically Integrated Pharmacy Accreditation

March 23, 2023 | Katie Edmiston

U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer

March 10, 2023 | Katie Edmiston

— First Trop-2 Directed ADC to Demonstrate Overall Survival Benefit in HR+/HER2- Metastatic Breast Cancer Patients who had Received Prior Endocrine-based Therapy and at Least Two Chemotherapies — — Trodelvy has Now Improved Survival in both Pre-Treated HR+/HER2- Metastatic Breast Cancer and in Second-Line Metastatic Triple-Negative Breast Cancer — FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. […]

NCODA International Executive Council to Advance Medically Integrated Oncology Worldwide

March 9, 2023 | Katie Edmiston

NCODA APPOINTS THREE NEW MEMBERS TO ITS EXECUTIVE COUNCIL

February 23, 2023 | Katie Edmiston

FOR IMMEDIATE RELEASE February 23, 2023 MEDIA CONTACT: Katie Edmiston Katie.Edmiston@ncoda.org 813-843-1629 NCODA APPOINTS THREE NEW MEMBERS TO ITS EXECUTIVE COUNCIL CAZENOVIA, NY – NCODA is delighted to announce the expansion of its Executive Council with the appointment of three appointed oncology healthcare leaders: Luis Campos, MD, John Marshall, MD, and Scott Freeswick, PharmD, […]

Fresenius Kabi launches biosimilar Stimufend® (pegfilgrastim-fpgk) in the U.S.

February 20, 2023 | Katie Edmiston

February 16, 2023 Fresenius Kabi’s first U.S. biosimilar launch Provides accessible, high-quality treatment option for U.S. cancer patients undergoing chemotherapy to reduce the incidence of infection as manifested by febrile neutropenia Strengthens Fresenius Kabi’s heritage in oncology and its commitment to oncology patients The expansion of the company’s global biosimilars portfolio focused on oncology and […]

Bipartisan Legislation In Support of Copay Assistance Counting For Patients

February 16, 2023 | Katie Edmiston

STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE (LPAC) Contact: Sarder Sadid, PharmD Phone: (315) 527-8590 Email: sarder.sadid@ncoda.org www.ncoda.org February 16, 2023 On February 9, 2023, US Representatives Earl L. “Buddy” Carter (R-GA), Nanette Barragan (D-CA), Mariannette Miller-Meeks (R-IA), and Diana DeGette (D-CO) introduced the Help Ensure Lower Patient (HELP) Copays Act to the House […]

Taiho Oncology is pleased to announce the commercial availability of LYTGOBI® (futibatinib) tablets.

February 13, 2023 | Katie Edmiston

Taiho Oncology is pleased to announce the commercial availability of LYTGOBI® (futibatinib) tablets. As we are ramping up to full supply, currently the 4mg tablet 35-count DosePak is available for prescribing via Onco360. The remaining two packages, 4mg tablet 28-count DosePak and 4mg tablet 21-count DosePak, will be available on or before April 1, 2023. […]

U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer

February 12, 2023 | Katie Edmiston

Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDU™ (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer

January 31, 2023 | Katie Edmiston

ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers. ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been difficult to treat. ORSERDU is the first endocrine innovation in more than 20 years, […]

Co-pay Accumulator Reform – HELP Copays Act (H.R. 5801)

January 26, 2023 | Katie Edmiston

FOR IMMEDIATE RELEASE January 26, 2023 Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 kevin.scorsone@ncoda.org www.ncoda.org Earlier this year, NCODA and the Patient Access Network (PAN) Foundation co-authored a letter to the United States House of Representatives focused on co-pay accumulator reform through the HELP Copays Act (H.R. 5801). PAN and […]

NCODA Launches Two New Multi-Specialty Medically Integrated Pharmacy Accreditation Programs

January 20, 2023 | Katie Edmiston

NCODA APPOINTS NEW MEMBERS TO EXECUTIVE COUNCIL

January 12, 2023 | Katie Edmiston

FOR IMMEDIATE RELEASE January 12, 2023 MEDIA CONTACT: Katie Edmiston Katie.Edmiston@ncoda.org 813-843-1629 CAZENOVIA, NY – NCODA, a non-profit organization whose Mission is to empower the medically-integrated oncology team to deliver positive, patient-centered outcomes – announces the appointment of three new members to its executive council: William Mitchell, MD, Lance Ortega, MBA, BSN, RN, […]

New NCODA Accredited Residency Program Provides Comprehensive Experience in Medically-Integrated Oncology Pharmacy

December 21, 2022 | Katie Edmiston

FOR IMMEDIATE RELEASE December 21, 2022 MEDIA CONTACT: Katie Edmiston Katie.Edmiston@ncoda.org 813-843-1629 CAZENOVIA, NY – NCODA, Inc. is excited to announce the creation of a new and innovative Accredited Medically-Integrated Oncology Pharmacy (MIOP) Residency Program. NCODA worked with cancer centers throughout the United States to provide the program framework and accreditation for this unique […]

STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE

December 16, 2022 | Katie Edmiston

FOR IMMEDIATE RELEASE December 16, 2022 Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org In a year that has seen plenty of legislative and political uncertainty, NCODA is proud of the Legislative & Policy Advisory Committee (LPAC) for maintaining their steadfast goal to educate our membership and shed […]

Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

December 14, 2022 | Katie Edmiston

12/12/2022 SAN DIEGO, Dec. 12, 2022 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for KRAZATI™ (adagrasib), a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received […]

New NCODA Program Equips Oncology Pharmacy Technicians with Premier Certification

December 8, 2022 | Katie Edmiston

FOR IMMEDIATE RELEASE December 8, 2022 MEDIA CONTACT: Katie Edmiston Katie.Edmiston@ncoda.org 813-843-1629 CAZENOVIA, NY – The need for oncology-focused pharmacy technician training has increased exponentially with advancements in the oral oncolytic landscape. To empower the entire medically-integrated oncology team and ensure an advanced level of patient care, NCODA’s Oncology Pharmacy Technician Association (OPTA) has […]

Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC)

November 14, 2022 | Katie Edmiston

Approval based on superior survival outcomes of Libtayo plus chemotherapy, compared to chemotherapy alone, in a patient population with a wide range of disease characteristics Second advanced NSCLC indication expands patient population eligible for a Libtayo-based regimen to include combination treatment with chemotherapy irrespective of PD-L1 expression levels TARRYTOWN, N.Y., Nov. 8, 2022 /PRNewswire/ — Regeneron Pharmaceuticals, […]

U.S. FDA Approves TECVAYLI™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

November 1, 2022 | Katie Edmiston

TECVAYLI™, an off-the-shelf, subcutaneous therapy, is an important new medicine for patients with incurable blood cancer who face limited treatment options HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed […]

NYOH Leads Rally In Response to Life Threatening Policy Change That Effects Cancer Patients

October 13, 2022 | Katie Edmiston

Cazenovia, NY (Oct 13, 2022) – With a recent policy change made to The New York State Department of Health’s (NYSDOH) Medicaid Pharmacy Program that prevents patients from obtaining their oral medication through their physician dispensary, practice leaders from New York Oncology Hematology (NYOH) immediately took action and led efforts to bring attention to this […]

Children with Chronic Graft Versus Host Disease (cGVHD) May Now Be Prescribed IMBRUVICA® (ibrutinib)

October 3, 2022 | Katie Edmiston

The U.S. Food and Drug Administration approved the use of IMBRUVICA for the treatment of pediatric patients one year and older with cGVHD after failure of one or more lines of systemic therapy This is the first approved treatment option for children with cGVHD under 12 years of age and the only Bruton’s tyrosine kinase […]

BIDEN MOONSHOT INITIATIVE FOCUSED ON CHANGING CANCER LANDSCAPE

September 13, 2022 | Katie Edmiston

FOR IMMEDIATE RELEASE September 13, 2022 STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org On the afternoon of Monday, September 12, President Biden arrived in Boston and made his way to the John F. Kennedy (JFK) Presidential Library. His visit […]

Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement

September 12, 2022 | Katie Edmiston

Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement August 26, 2022 – This marks the second indication for Pemazyre, which received accelerated FDA approval in 2020 for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor […]

SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022

September 12, 2022 | Katie Edmiston

SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022 – Nirogacestat Treatment Resulted in Rapid, Sustained and Statistically Significant Improvements in Primary and All Key Secondary Efficacy Endpoints – – NDA Submission to the U.S. FDA […]

MAINE CONTINUES REFORM FOR PATIENTS

September 6, 2022 | Katie Edmiston

FOR IMMEDIATE RELEASE September 6, 2022 STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org In two consecutive legislative sessions in 2021 and 2022, the state of Maine has focused on reform for patients battling cancer. The legislative bodies in Maine […]

Children with Chronic Graft Versus Host Disease (cGVHD) May Now Be Prescribed IMBRUVICA® (ibrutinib)

August 26, 2022 | Katie Edmiston

New Approval Alert The U.S. Food and Drug Administration approved the use of IMBRUVICA® (ibrutinib) for the treatment of pediatric patient one year and older with cGvHD after failure of one or more lines of systemic therapy. Official statement HERE.

Defining Appropriate Quality Performance Metrics for Pharmacies Dispensing Oral Oncology Therapies

August 19, 2022 | Katie Edmiston

NCODA applauds the recent published article in the American Journal of Managed Care® by our members at Florida Cancer Specialists and Research Institute titled “Defining Appropriate Quality Performance Metrics for Pharmacies Dispensing Oral Oncology Therapies.” Click the link below to read this article: https://www.ajmc.com/view/defining-appropriate-quality-performance-metrics-for-pharmacies-dispensing-oral-oncology-therapies

NCODA and Florida Cancer Specialists & Research Institute Announce New Oncology Stakeholder Education Exchange Program

August 16, 2022 | Katie Edmiston

Cazenovia, NY, August 16, 2022 – New cancer treatment therapies, technologies and innovations continue to be discovered and approved for use at a rapid pace, creating an education challenge for physicians and other healthcare professionals within the complex oncology landscape. Working collaboratively with Florida Cancer Specialists & Research Institute, LLC (FCS), NCODA, Inc. developed a […]